Junichi Fukute

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Prestwick Pharmaceuticals, Inc. develops drugs for diseases related to the central nervous system. Its drugs are used in curing diseases such as Huntington's, Parkinson's, restless legs syndrome, schizophrenia, autism, Alzheimer's, and sleep apnea diseases. The company was founded in 2002 and is headquartered in Washington DC.

Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL.

Arrow Therapeutics Ltd. operates as a pharmaceutical company that focuses on research and development of novel antiviral drugs. Its products include novel antibacterial, antiviral, antifungal and preclinical compounds. The company was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

NEO New Oncology GmbH provides molecular diagnostics-based services. Its cancer genome diagnostic platform include The NEO Technology, NEOplus and NEOliquid which support pathologists and oncologists with comprehensive molecular information to help select targeted cancer therapies. The company was founded by Roman Thomas and Axel Ullrich in 2012 and is headquartered in Cologne, Germany.

Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI.

Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland.

Actelion Pharmaceuticals UK Ltd. discovers, develops, and markets drugs. Its products are Tracleer for the treatment of pulmonary arterial hypertension and Zavesca, which is used to treat Type 1 Gaucher disease. The company is headquartered in London, UK.

Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland.

SciRhom GmbH engages in the development of treatment for life-threatening diseases. The company was founded by Andreas Jenne, Jens Ruhein, Axel Ullrich, Carl Blobel and Matthias Schneider in 2016 and is headquartered in Planegg, Germany.